CJC-1295 (with DAC) CD
GHRH analogue, albumin-binding
GHRH analogue with a drug affinity complex (DAC) linker that binds serum albumin, giving a reported half-life of roughly a week.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GHRH analogue, albumin-binding
- Category
- Growth Hormone Axis
- Type
- Single compound
- Abbreviation
- CD
- Development and regulatory status
- Not approved; investigational research compound
What researchers study
GHRH analogue with amino-acid substitutions and a drug affinity complex (DAC) linker that binds serum albumin, extending its half-life to roughly a week (reported 5.8 to 8.1 days). It stimulates the pituitary GHRH receptor.
Research areas
- Sustained GHRH receptor activation in healthy-volunteer studies
- Growth hormone pulsatility during continuous stimulation
- Albumin-binding peptide pharmacokinetics
- GH and IGF-I axis responses
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- human trial
In two placebo-controlled trials in healthy adults, single administrations raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold
- human trial
After a single administration in healthy men, GH pulse frequency and magnitude were unaltered while basal trough GH rose 7.5-fold, so pulsatility persisted
- human trial
No serious adverse reactions were reported in the two trials
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- CJC-1295 (no DAC)short-acting counterpart for pulsatile versus sustained comparisons
- Ipamorelinghrelin-receptor agonist often studied alongside GHRH analogues
- Tesamorelinstabilised GHRH analogue used as a comparator
